Table 2.
Number of OGLDs taken at baseline and following 24 weeks of therapy with biphasic insulin aspart 30
| Number of OGLDs | ≤40 years | >40–65 years | >65 years | |||
|---|---|---|---|---|---|---|
| Baseline | 24 weeks | Baseline | 24 weeks | Baseline | 24 weeks | |
| All, n | 4,347 | 3,620 | 29,036 | 25,134 | 6,739 | 5,688 |
| No OGLDs, n (% of cohort) | 1,629 (37.5) | 1,166 (32.2) | 8,421 (29.0) | 6,489 (25.8) | 2,815 (41.8) | 2,256 (39.7) |
| One OGLD, n (% of cohort) | 1,654 (38.0) | 1,388 (38.3) | 13,000 (44.8) | 11,240 (44.7) | 2,677 (39.7) | 2,420 (42.5) |
| ≥Two OGLDs, n (% of cohort) | 1,064 (24.5) | 1,066 (29.4) | 7,615 (26.2) | 7,405 (29.5) | 1,247 (18.5) | 1,012 (17.8) |
Due to the non-interventional nature of this study, not all baseline data were recorded and some patients were lost to follow-up
OGLDs oral glucose-lowering drugs